Wenger Vieli with NLS Pharmaceutics

Wenger Vieli acted as Swiss legal advisor to NLS Pharmaceutics on all Swiss legal matters in connection with the direct offering and concurrent private placement transaction with certain investors to issue 806,452 of common shares and 806,452 of common share warrants for aggregate gross proceeds of USD 3.2 million, and 806,452 of preferred shares in exchange for the satisfaction of the Company’s debt in the aggregate amount of USD 4.0 mio pursuant to certain securities purchase agreements.

Wenger Vieli’s team

The legal team was led by M&A/ transactions partner Pascal Honold (pictured) and included Bruno Mahler (associate, M&A/ transactions, notarial services), Elisha Odenheimer (Associate, M&A/ Transactions), Andrea Christen (Associate, Notarial Services), Marc Schumacher (Junior Lawyer) and Pepe Hünerwadel (Legal Practitioner). The tax team was led by Dominik Bürgy (Partner, Tax) and included Jonas Bühlmann (counsel, tax).

The net proceeds from this transaction will be used for working capital and general corporate purposes, supporting the company’s commitment to advancing its portfolio and operational capabilities.

NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders.